Modality
Small Molecule
MOA
FGFRi
Target
CD38
Pathway
Amyloid
FLPNHOvarian Ca
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
Jul 2021
→ May 2026
Phase 2Current
NCT05453203
98 pts·Ovarian Ca
2021-07→2026-05·Terminated
98 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-101mo awayPh3 Readout· Ovarian Ca
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2/3
Termina…
Catalysts
Ph3 Readout
2026-05-10 · 1mo away
Ovarian Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05453203 | Phase 2/3 | Ovarian Ca | Terminated | 98 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |